Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Advertisement
Patrick DalyChronic Lymphocytic Leukemia | November 28, 2023
Patients with CLL who progressed after ibrutinib and venetoclax did not show mutations linked with treatment resistance.
Read More
Patrick DalyChronic Lymphocytic Leukemia | November 28, 2023
Nemtabrutinib induced a response in 75% of patients with CLL, and investigators established a phase II dose of 65 mg daily.
Patrick DalyChronic Lymphocytic Leukemia | November 28, 2023
A time-limited regimen including a PI3K inhibitor was safe and highly effective in patients with relapsed or refractory CLL.
Patrick DalyChronic Lymphocytic Leukemia | October 27, 2023
BCL-2 protein hyperphosphorylation underlies both intrinsic and acquired resistance to venetoclax in CLL, study finds.
Patrick DalyChronic Lymphocytic Leukemia | October 27, 2023
The GIVe regimen of obinutuzumab, ibrutinib, and venetoclax was a promising first-line, fixed-duration treatment for CLL.
Patrick DalyChronic Lymphocytic Leukemia | October 27, 2023
Higher effector T-cell counts induced cytotoxic activity and more favorable responses to ibrutinib and rituximab in CLL.
Advertisement
Cailin ConnerChronic Lymphocytic Leukemia | September 22, 2023
The primary endpoints of the phase III ELEVATE-RR study were PFS, AEs, and events of clinical interest.
Cailin ConnerChronic Lymphocytic Leukemia | September 22, 2023
Reseserchers with the German CLL Study Group conducted a prospective analysis of karyotype complexity in patients with CLL.
Cailin ConnerChronic Lymphocytic Leukemia | September 22, 2023
Patients with mutated IGHV had a median PFS of 14.6 years compared with 4.2 years in patients with unmutated IGHV.
Cecilia BrownChronic Lymphocytic Leukemia | September 20, 2023
Dr. Coombs discusses her journey into oncology, what it’s like to broach the lymphoid and myeloid worlds, and a unique ...
Othman Al-Sawaf, MDChronic Lymphocytic Leukemia | September 20, 2023
Othman Al-Sawaf, MD, and Nicole Lamanna, MD, debate approaches in this Point | Counterpoint.
Mary Ann Anderson, MBBS, PhDChronic Lymphocytic Leukemia | September 19, 2023
Mary Ann Anderson, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses the importance of World CLL Day.
Alessandra Ferrajoli, MDMeeting News | September 14, 2023
Alessandra Ferrajoli, MD, discusses her presentation on the topic during the Eleventh Annual Meeting of SOHO.
Mary Ann Anderson, MBBS, PhDMeeting News | September 13, 2023
Dr. Anderson spoke about her plenary session on the topic at the Eleventh Annual Meeting of SOHO.
Cecilia BrownChronic Lymphocytic Leukemia | September 11, 2023
All patients included in the study required treatment and had not previously received psychiatric treatment.
Cecilia BrownMeeting News | September 11, 2023
The study included patients with relapsed or refractory B-cell malignancies who were in the phase I/II BRUIN trial.
Cecilia BrownChronic Lymphocytic Leukemia | September 11, 2023
The researchers investigated if iso-cel in patients with relapsed or refractory CLL is a cost-efficient option.
Cailin ConnerMeeting News | September 10, 2023
Noteworthy regional disparities were noticed in treatment strategies.
Cailin ConnerChronic Lymphocytic Leukemia | September 10, 2023
Investigators from the Mayo Clinic identified 145 patients with CLL who were treated between 2014-2021.
Cecilia BrownChronic Lymphocytic Leukemia | September 7, 2023
Dr. Brown shares what CLL news and session she's watching at the Eleventh Annual Meeting of SOHO.
Advertisement
Advertisement
Editorial Board